Vaccination of Macaques against Pathogenic Simian Immunodeficiency Virus with Venezuelan Equine Encephalitis Virus Replicon Particles

Davis, Nancy; Caley, Ian J.; Brown, Kevin; Betts, Michael R.; Irlbeck, David M.; McGrath, Kathryn M.; Connell, Mary J.; Montefiori, David C.; Frelinger, Jeffrey A.; Swanstrom, Ronald; Johnson, Philip R.; Johnston, Robert E.

doi:10.1128/jvi.74.1.371-378.2000

Cited by 186 publications

(48 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…bacterial (Chlamydia pneumoniae (Penttila et al, 2004) and Brucella Abortus (Onate et al, 2005)) and parasitic diseases (Plasmodium Falciparum (Andersson et al, 2001;Chen et al, 2004)). Similarly, rSIN and rVEE have been studied as vectors for the induction of immune responses against HIV and SIV (Davis et al, 2000;Dong et al, 2003;Gupta et al, 2005;Vajdy et al, 2001), HPV E7 (Cassetti et al, 2004;Cheng et al, 2002;Lin et al, 2003;Velders et al, 2001), Norwalk virus (Harrington et al, 2002), Equine Arteritis virus in horses (Balasuriya et al, 2002) Anthrax , Staphylococcus (Lee et al, 2002) and Mycobacterium tuberculosis (Kirman et al, 2003).…”

Section: Immunization Strategies Against Infectious Diseasementioning

confidence: 98%

Recombinant alphaviruses as vectors for anti-tumour and anti-microbial immunotherapy

Riezebos‐Brilman

Mare

Bungener

et al. 2006

Journal of Clinical Virology

View full text Add to dashboard Cite

Section: Immunization Strategies Against Infectious Diseasementioning

confidence: 98%

Recombinant alphaviruses as vectors for anti-tumour and anti-microbial immunotherapy

Riezebos‐Brilman

Mare

Bungener

et al. 2006

Journal of Clinical Virology

View full text Add to dashboard Cite

“…[26][27][28] In parallel, the entire gag gene was chemically synthesized, altering the codons to represent optimized human codon usage (hu-gag). VEE replicon particles (VRPs) were generated as previously described 18 and used to infect BHK cells and VERO cells, and Gag expression was monitored after gel electrophoresis by both staining for protein mass and by Western blot analysis. Large amounts of p55 Gag protein accumulated in the cells (Fig.…”

Section: Expression Of Gag and Env Genes In The Vee Vectormentioning

confidence: 99%

“…This approach has been shown to elicit both CTL and antibody responses and was able to reduce virus load and disease progression in an SIV challenge experiment. 18 This study aimed to identify representative, recently transmitted HIV-1 subtype C isolates for use in the development of vaccines targeted for South Africa and the southern African region, and to provide an efficient strategy for surveying sequence diversity among circulating viruses. Genes from these isolates were cloned into VRP expression vectors and tested for immunogenicity and function.…”

Section: Introduction T Here Is Intense Interest In the Development Omentioning

confidence: 99%

Characterization and Selection of HIV-1 Subtype C Isolates for Use in Vaccine Development

Williamson

Morris²,

Maughan

et al. 2003

AIDS Research and Human Retroviruses

Self Cite

113

View full text Add to dashboard Cite

HIV-1 genetic diversity among circulating strains presents a major challenge for HIV-1 vaccine development, particularly for developing countries where less sequence information is available. To identify representative viruses for inclusion in candidate vaccines targeted for South Africa, we applied an efficient sequence survey strategy to samples from recently and chronically infected persons residing in potential vaccine trial sites. All 111 sequences were subtype C, including 30 partial gag, 26 partial pol, 27 V2-V3 env, and 28 V5-partial gp41 sequences. Of the 10 viruses cultured from recently infected individuals, 9 were R5 and 1 was R5X4. Two isolates, Du151 and Du422, collected within 2 months of infection, were selected as vaccine strains on the basis of their amino acid similarity to a derived South African consensus sequence The selection of recently transmitted R5 isolates for vaccine design may provide an advantage in a subtype C R5-dominant epidemic. The full-length Du422 gag and Du151 pol and env genes were cloned into the Venezuelan equine encephalitis (VEE) replicon particle (VRP) expression system. Du422 Gag protein expressed from the VRP accumulated to a high level and was immunogenic as demonstrated by cytotoxic T lymphocyte responses in mice vaccinated with gag-VRPs. Optimization of codon use for VRP expression in human cells did not enhance expression of the gag gene. The cloned Du151 env gene encoded a functional protein as demonstrated by fusion of VRP-infected cells with cells expressing CD4 and CCR5. Genes identified in this study have been incorporated into the VEE VRP candidate vaccines targeted for clinical trial in South Africa.

show abstract

“…More recently, the VRP vector has been evaluated in the rat neu transgenic mouse model [37], as noted above a potentially less stringent model than rats, with significant anti-tumor activity including the ability to treat developed tumors. These reports and the ability of this vector system to elicit CTL/Th1 biased immune responses [38,[77][78][79][80][81] in ID models lends additional support to the potency and efficacy of the VRP vector system.…”

Section: Discussionmentioning

confidence: 64%

VRP immunotherapy targeting neu: treatment efficacy and evidence for immunoediting in a stringent rat mammary tumor model

Laust

Sur

Wang

et al. 2007

Breast Cancer Res Treat

View full text Add to dashboard Cite

The ability to overcome intrinsic tolerance to a strict "self" tumor-associated antigen (TAA) and successfully treat pre-existing tumor is the most stringent test for anti-tumor immunotherapeutic strategies. Although this capacity has been demonstrated in various models using complicated strategies that may not be readily translated into the clinical arena, straightforward antigen-specific immunotherapeutic strategies in the most stringent models of common epithelial cancers have largely failed to meet this standard. We employed an immunotherapeutic strategy using an alphavirus-based, virus-like replicon particle (VRP), which has in vivo tropism for dendritic cells, to elicit immune responses to the non-mutated TAA rat neu in an aggressive rat mammary tumor model. Using this VRP-based immunotherapeutic strategy targeting a single TAA, we generated effective anti-tumor immunity in the setting of pre-existing tumor resulting in the cure of 36% of rats over multiple experiments, P = 0.002. We also observed down-regulation of rat neu expression in tumors that showed initial responses followed by tumor escape with resumption of rapid tumor growth. These responses were accompanied by significant anti-tumor proliferative responses and CD8+ cellular tumor infiltrates, all of which were restricted to animals receiving the anti-neu immunotherapy. Together these data, obtained in a stringent "self" TAA model, indicate that the VRP-based antigen-specific immunotherapy elicits sufficiently potent immune responses to exert immunologic pressure, selection, and editing of the growing tumors, thus supporting the activity of this straightforward immunotherapy and suggesting that it is a promising platform upon which to build even more potent strategies.

show abstract

Vaccination of Macaques against Pathogenic Simian Immunodeficiency Virus with Venezuelan Equine Encephalitis Virus Replicon Particles

Cited by 186 publications

References 47 publications

Recombinant alphaviruses as vectors for anti-tumour and anti-microbial immunotherapy

Recombinant alphaviruses as vectors for anti-tumour and anti-microbial immunotherapy

Characterization and Selection of HIV-1 Subtype C Isolates for Use in Vaccine Development

VRP immunotherapy targeting neu: treatment efficacy and evidence for immunoediting in a stringent rat mammary tumor model

Contact Info

Product

Resources

About